Unicharm (OTCMKTS:UNICY – Get Free Report) and Medifast (NYSE:MED – Get Free Report) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Unicharm and Medifast’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicharm | 6.21% | 6.70% | 4.93% |
| Medifast | -13.64% | -6.90% | -5.34% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Unicharm and Medifast, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicharm | 0 | 2 | 0 | 0 | 2.00 |
| Medifast | 1 | 2 | 0 | 0 | 1.67 |
Medifast has a consensus target price of $12.00, indicating a potential downside of 4.12%. Given Medifast’s higher probable upside, analysts plainly believe Medifast is more favorable than Unicharm.
Earnings & Valuation
This table compares Unicharm and Medifast”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicharm | $6.32 billion | 1.96 | $436.93 million | $0.12 | 29.67 |
| Medifast | $299.57 million | 0.47 | -$18.67 million | ($3.69) | -3.39 |
Unicharm has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Unicharm, indicating that it is currently the more affordable of the two stocks.
Dividends
Unicharm pays an annual dividend of $0.04 per share and has a dividend yield of 1.1%. Medifast pays an annual dividend of $6.60 per share and has a dividend yield of 52.7%. Unicharm pays out 33.3% of its earnings in the form of a dividend. Medifast pays out -178.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medifast is clearly the better dividend stock, given its higher yield and lower payout ratio.
Risk & Volatility
Unicharm has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Medifast has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Insider and Institutional Ownership
95.5% of Medifast shares are held by institutional investors. 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Unicharm beats Medifast on 9 of the 15 factors compared between the two stocks.
About Unicharm
Unicharm Corporation is a Japanese manufacturer of hygiene and personal care products. Its offerings include baby diapers and related products, feminine care products, and adult incontinence and other healthcare products. The company also sells pet-care products, including pet food and hygiene supplies, as well as household and cleaning products. Unicharm’s brands serve consumers in Japan and international markets, particularly across Asia, with operations and sales spanning additional regions. Founded in Japan in 1961, Unicharm has expanded from its domestic roots into a global consumer-products business.
About Medifast
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.
Receive News & Ratings for Unicharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicharm and related companies with MarketBeat.com's FREE daily email newsletter.
